Cepheid announces expanded access to Xpert family of virology tests in global regions with the greatest need

SUNNYVALE, CALIF. — July 23, 2018 — Cepheid has announced that under its HBDC Access Program1, the company will immediately lower the price of Xpert® tests used for molecular diagnosis of human immunodeficiency virus (HIV), viral hepatitis (HCV) and human papilloma virus (HPV)2 to US $14.90, to make the tests more accessible to lower-income countries.

Cepheid cited the increasing popularity of the GeneXpert® System, as well as the technology’s enormous potential for quickly diagnosing multiple diseases in individual patients, as important factors in the decision to update the HBDC Access Program.

"Cepheid’s new pricing is intended to help programmes bring cutting-edge care closer to the homes for more of the millions of people known to be affected by these diseases — yet are so-far undiagnosed," said Philippe Jacon, Senior Vice President of Global Access at Cepheid. "Pricing standardisation will also simplify budgeting and procurement for national programmes."

The more than 10,000 GeneXpert Systems that have been installed in low and middle-income countries, mainly for the diagnosis of active tuberculosis, can also be used to test for the multiple conditions on the virology menu included in the new pricing agreement.

Control of global health threats may be hampered when testing is performed in centralized labs far from where patients live. Patients often travel long distances for diagnostic testing, or their samples must be transported — which may delay test results and impact patient care. Moreover,  test results may get lost or never make it back to the patients.

Decentralisation of testing facilities increases access and improves patient outcomes, as shown by recent studies from countries like Malawi3, where infants were tested for HIV both immediately at the point of care and by sending samples to a remote laboratory. More results were delivered to clinicians and more babies treated when tested locally. 

Global health organizations, countries, donors and other stakeholders have been encouraging and supporting the more integrated, efficient use of diagnostics to work toward WHO targets for eliminating diseases such as HIV, tuberculosis, HCV and cervical cancer.

"Unitaid has made significant investments in advancing integration in molecular diagnostics. Integrating care means more people healed, more lives saved, more efficient use of resources," Unitaid Executive Director Lelio Marmora said. "Now we need manufacturers to share in the responsibility of making sure these technologies work seamlessly in countries as part of sustainable systems."


1. HBDC Access Program covers 130 Low and Middle-income countries. Conditions can be found on the FIND website (https://www.finddx.org/find-negotiated-product-pricing/)
2. Products not available in the US
3. Mwenda et al. Significantly improved antiretroviral therapy initiation rates after implementation of Point of Care Early Infant Diagnosis. ASLM 2016


About Cepheid

Based in Sunnyvale, Calif., Cepheid is a leading molecular diagnostics company dedicated to improving healthcare by developing, manufacturing, and marketing accurate yet easy-to-use molecular systems and tests. By automating highly complex and time-consuming manual procedures, the company’s solutions deliver a better way for institutions of any size to perform sophisticated genetic testing for organisms and genetic-based diseases. Through its strong molecular biology capabilities, the company is focusing on those applications where accurate, rapid, and actionable test results are needed most, such as managing infectious diseases and cancer. For more information, visit http://www.cepheid.com.